Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
AstraZeneca
Fuji
Medtronic
QuintilesIMS
Queensland Health
UBS
Merck
Daiichi Sankyo

Generated: October 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 6,342,515

« Back to Dashboard

Claims for Patent: 6,342,515

Title: Remedy for neurodegenerative diseases
Abstract:The present invention provides a medicament for neurodegenerative diseases comprising zonisamide or an alkali metal salt thereof as an active ingredient. The present medicament can be used in the prevention and treatment of neurodegenerative diseases such as Parkinson's disease, Huntington's disease, choreic syndrome and dystonic syndrome in mammals (including human).
Inventor(s): Masuda; Yoshinobu (Katano, JP), Ochi; Yoshiaki (Sanda, JP)
Assignee: Dainippon Pharmaceutical Co., Ltd. (Osaka-fu, JP)
Application Number:09/582,433
Patent Claims: 1. A method for the prevention and/or treatment of neurodegenerative diseases in a mammal which comprises administering an effective amount of zonisamide or an alkali metal salt thereof to said mammal in need of such prevention and/or treatment.

2. The method for the prevention and/or treatment according to claim 1, wherein the neurodegenerative disease is Parkinson's disease.

3. The method for the prevention and/or treatment according to claim 1, wherein the daily dosage is in the range of 1 to 50 mg per kg of body weight of a mammal.

4. The method for the prevention and/or treatment according to claim 3, wherein the daily dosage is in the range of 2 to 20 mg per kg of body weight of a mammal.

5. The method for the prevention and/or treatment according to claim 2, wherein the daily dosage is in the range of 1 to 5 mg per kg of body weight of a mammal.

6. A The method for the prevention and/or treatment according to claim 5, wherein the daily dosage is in the range of 2 to 20 mg per kg of body weight of a mammal.

7. The method for the prevention and/or treatment according to claim 1, wherein the mammal is human.

8. The method for the prevention and/or treatment according to claim 2, wherein the mammal is human.

9. The method for the prevention and/or treatment according to claim 3, wherein the mammal is human.

10. The method for the prevention and/or treatment according to claim 4, wherein the mammal is human.

11. The method for the prevention and/or treatment according to claim 5, wherein the mammal is human.

12. The method for the prevention and/or treatment according to claim 6, wherein the mammal is human.

13. A method for the prevention and/or treatment of neurodegenerative diseases in a mammal which comprises administering an effective amount of zonisamide to said mammal in need of such prevention and/or treatment.

14. The method for the prevention and/or treatment according to claim 13, wherein the neurodegenerative disease is Parkinson's disease.

15. The method for the prevention and/or treatment according to claim 13, wherein the daily dosage is in the range of 1 to 50 mg per kg of body weight of a mammal.

16. The method for the prevention and/or treatment according to claim 15, wherein the daily dosage is in the range of 2 to 20 mg per kg of body weight of a mammal.

17. The method for the prevention and/or treatment according to claims 14, wherein the daily dosage is in the range of 1 to 50 mg per kg of body weight of a mammal.

18. The method for the prevention and/or treatment according to claim 17, wherein the daily dosage is in the range of 2 to 20 mg per kg of body weight of a mammal.

19. The method for the prevention and/or treatment according to claim 13, wherein the mammal is human.

20. The method for the prevention and/or treatment according to claim 14, wherein the mammal is human.

21. The method for the prevention and/or treatment according to claim 15, wherein the mammal is human.

22. The method for the prevention and/or treatment according to claim 16, wherein the mammal is human.

23. The method for the prevention and/or treatment according to claim 17, wherein the mammal is human.

24. The method for the prevention and/or treatment according to claim 18, wherein the mammal is human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cipla
McKinsey
US Army
Boehringer Ingelheim
Daiichi Sankyo
Chubb
Farmers Insurance
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot